HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer

This article was originally published in The Tan Sheet

Executive Summary

Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany

You may also be interested in...

Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains

Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27

Bayer Attributes Recent Aleve Bounce To Advisory Panel Discussions

Bayer credits a rebound in Aleve sales in March to favorable FDA advisory committee discussions on the safety of naproxen

Naproxen May Be “Exception” To NSAID Rule, But Data Is Lacking – FDA

An FDA memorandum released April 15 points to naproxen as a potentially safer NSAID compared to other drugs in the class

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts